Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Status:
Recruiting
Trial end date:
2027-09-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate
the tumor when injected into the body, and whether T-DXd may be an effective treatment for
brain cancers that express the HER2 protein.